XML 200 R67.htm IDEA: XBRL DOCUMENT v3.25.0.1
Significant transactions (Details)
$ / shares in Units, € in Millions
3 Months Ended 12 Months Ended
Oct. 17, 2024
USD ($)
Jul. 01, 2024
USD ($)
Dec. 06, 2022
USD ($)
Nov. 21, 2022
USD ($)
$ / shares
Jul. 08, 2022
USD ($)
product
May 31, 2022
USD ($)
May 31, 2022
EUR (€)
Jan. 07, 2022
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2024
EUR (€)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
May 31, 2022
EUR (€)
May 30, 2022
USD ($)
Disclosure of detailed information about business combination [line items]                                  
Goodwill                 $ 8,946,000,000 $ 8,946,000,000 $ 8,926,000,000 $ 8,926,000,000          
Consideration paid for acquisition of businesses                   61,000,000 0 $ 666,000,000          
Borrowings                 $ 4,643,000,000 $ 4,643,000,000 4,739,000,000            
Eysuvis and Inveltys                                  
Disclosure of detailed information about business combination [line items]                                  
Acquisition of assets, number of products acquired | product         2                        
Acquisition of assets, upfront consideration         $ 60,000,000                        
Inventory, net of liabilities         14,000,000                        
Purchase consideration         79,000,000                        
Intangible assets         $ 71,000,000                        
Ivantis, Inc.                                  
Disclosure of detailed information about business combination [line items]                                  
Percentage of voting equity interests acquired (as a percent)               100.00%                  
Acquisition of assets, upfront consideration               $ 479,000,000                  
Series 2032 Notes                                  
Disclosure of detailed information about business combination [line items]                                  
Borrowings     $ 700,000,000                            
Borrowings, interest rate (as a percent)     5.375%           5.375% 5.375%     5.375%        
Series 2052 Notes                                  
Disclosure of detailed information about business combination [line items]                                  
Borrowings     $ 600,000,000                            
Borrowings, interest rate (as a percent)     5.75%           5.75% 5.75%     5.75%        
Facility B Term Loan                                  
Disclosure of detailed information about business combination [line items]                                  
Borrowings                                 $ 800,000,000
Repayments of non-current borrowings     $ 640,000,000     $ 160,000,000                      
Bridge Loan Facility                                  
Disclosure of detailed information about business combination [line items]                                  
Borrowings       $ 775,000,000                          
Repayments of non-current borrowings     $ 775,000,000                            
Series 2028 Notes                                  
Disclosure of detailed information about business combination [line items]                                  
Borrowings           $ 537,000,000     $ 521,000,000 $ 521,000,000     € 500     € 500  
Borrowings, interest rate (as a percent)           2.375%     2.375% 2.375%     2.375%     2.375%  
Facility C Term Loan                                  
Disclosure of detailed information about business combination [line items]                                  
Repayments of non-current borrowings           $ 376,000,000 € 350                    
BELKIN Vision Ltd.                                  
Disclosure of detailed information about business combination [line items]                                  
Percentage of voting equity interests acquired (as a percent)   100.00%                              
Goodwill   $ 20,000,000                       $ 20,000,000      
Consideration transferred   92,000,000                       92,000,000      
Previously-held FVOCI financial investments   20,000,000                       $ 20,000,000      
Consideration paid for acquisition of businesses   $ 61,000,000             $ 1,000,000                
Aerie Pharmaceuticals, Inc.                                  
Disclosure of detailed information about business combination [line items]                                  
Percentage of voting equity interests acquired (as a percent)       100.00%                          
Goodwill       $ 65,000,000             21,000,000       $ 21,000,000    
Consideration transferred       744,000,000             744,000,000            
Consideration paid for acquisition of businesses       $ 666,000,000                          
Price paid (in dollars per share) | $ / shares       $ 15.25                          
Borrowings recognised as of acquisition date       $ 316,200,000             $ 316,000,000            
China divestment of product rights and out-licensing                                  
Disclosure of detailed information about business combination [line items]                                  
Divestment, value of ordinary shares received $ 116,000,000                                
Divestment, percentage of ordinary shares received 16.70%